CU20180014A7 - Inhibidor de la isocitrato deshidrogenasa mutada idh1 r132h - Google Patents

Inhibidor de la isocitrato deshidrogenasa mutada idh1 r132h

Info

Publication number
CU20180014A7
CU20180014A7 CUP2018000014A CU20180014A CU20180014A7 CU 20180014 A7 CU20180014 A7 CU 20180014A7 CU P2018000014 A CUP2018000014 A CU P2018000014A CU 20180014 A CU20180014 A CU 20180014A CU 20180014 A7 CU20180014 A7 CU 20180014A7
Authority
CU
Cuba
Prior art keywords
idh1
inhibitor
muted
isocitrate
dehydrogenase
Prior art date
Application number
CUP2018000014A
Other languages
English (en)
Inventor
Heiko Schirmer
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of CU20180014A7 publication Critical patent/CU20180014A7/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30Nitrogen atoms not forming part of a nitro radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

<p>La presente invención se refiere al adcuto del ácido (2E)-but-2-enedioico y ácido 3-(2-{[4- (trifluorometoxi)fenil] amino}-1-[(1R,5R)-3,3,5-trimetilciclohexil]-1 H-benzimidazol-5- il)propanoico (1:4) y a su forma cristalina, a un método para preparar este aducto, y a medicamentos que comprenden este aducto, el cual es un inhibidor de la isocitrato deshidrogenasa mutada IDH1 R132H útil para el tratamiento de tumores.</p>
CUP2018000014A 2015-07-27 2016-07-22 Inhibidor de la isocitrato deshidrogenasa mutada idh1 r132h CU20180014A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15178419 2015-07-27
PCT/EP2016/067477 WO2017016992A1 (en) 2015-07-27 2016-07-22 Inhibitor of the mutated isocitrate dehydrogenase idh1 r132h

Publications (1)

Publication Number Publication Date
CU20180014A7 true CU20180014A7 (es) 2018-06-05

Family

ID=53758092

Family Applications (1)

Application Number Title Priority Date Filing Date
CUP2018000014A CU20180014A7 (es) 2015-07-27 2016-07-22 Inhibidor de la isocitrato deshidrogenasa mutada idh1 r132h

Country Status (26)

Country Link
US (1) US10344004B2 (es)
EP (1) EP3328837B1 (es)
JP (1) JP6804516B2 (es)
KR (1) KR20180030789A (es)
CN (1) CN107810181B (es)
AR (1) AR105493A1 (es)
AU (1) AU2016300980B2 (es)
BR (1) BR112018001534A2 (es)
CA (1) CA2993473A1 (es)
CL (1) CL2018000249A1 (es)
CO (1) CO2018000793A2 (es)
CR (1) CR20180053A (es)
CU (1) CU20180014A7 (es)
DO (1) DOP2018000027A (es)
EA (1) EA201890386A1 (es)
EC (1) ECSP18006465A (es)
ES (1) ES2860693T3 (es)
HK (1) HK1252449A1 (es)
IL (1) IL256024A (es)
MX (1) MX2018001205A (es)
NI (1) NI201800014A (es)
PE (1) PE20181038A1 (es)
SV (1) SV2018005621A (es)
TN (1) TN2018000038A1 (es)
TW (1) TW201708193A (es)
WO (1) WO2017016992A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9951027B2 (en) 2014-02-11 2018-04-24 Bayer Pharma Aktiengesellschaft Benzimidazol-2-amines as MIDH1 inhibitors
EA031655B1 (ru) 2014-02-11 2019-02-28 Байер Фарма Акциенгезельшафт Бензимидазол-2-амины в качестве ингибиторов midhi
JP6672288B2 (ja) 2014-10-23 2020-03-25 バイエル・ファルマ・アクティエンゲゼルシャフト 腫瘍の治療のためのmidh1阻害剤としての1−シクロヘキシル−2−フェニルアミノベンゾイミダゾール
EP3303302B1 (en) 2015-06-08 2019-03-20 Bayer Pharma Aktiengesellschaft N-menthylbenzimidazoles as midh1 inhibitors
EP3319945B1 (en) 2015-07-07 2021-04-28 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts 2-aryl- and 2-arylalkyl-benzimidazoles as midh1 inhibitors
JP6824954B2 (ja) 2015-07-16 2021-02-03 ドイチェス クレープスフォルシュングスツェントルム シュティフトゥング デス エッフェントリッヒェン レヒツ mIDH1阻害剤としての5−ヒドロキシアルキルベンズイミダゾール
EP3121166A1 (en) 2015-07-21 2017-01-25 Bayer Pharma Aktiengesellschaft Fused imidazoles as midh1 inhibitors
TW201718513A (zh) 2015-07-27 2017-06-01 拜耳製藥公司 製備經取代之3-(2-苯胺-1-環己基-1h-苯并咪唑-5-基)丙酸衍生物之方法
WO2019015672A1 (zh) * 2017-07-21 2019-01-24 南京明德新药研发股份有限公司 吡啶并咪唑类化合物及其应用
US20210113598A1 (en) 2017-08-01 2021-04-22 Deutsches Krebsforschungszentrum (DKFZ) Stiftung des öffentlichen Rechts Combination of MIDH1 Inhibitors and DNA Hypomethylating Agents (HMA)
CN108948205B (zh) * 2018-07-13 2021-09-28 北京金岱生物科技有限公司 抗idh1r132h单克隆抗体及其应用
TWI760017B (zh) 2019-12-23 2022-04-01 大陸商昆藥集團股份有限公司 一種idh1突變體抑制劑的鹽型、晶型及其製備方法
EP4186525A4 (en) 2020-07-21 2024-04-03 Daiichi Sankyo Company, Limited COMBINATION OF TEMOZOLOMIDE AND INHIBITOR OF THE MUTANT IDH1 ENZYME

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010263113B2 (en) * 2009-06-23 2015-11-26 Translational Drug Development, Llc Benzamide derivatives
US9012464B2 (en) * 2010-11-25 2015-04-21 Ratiopharm Gmbh Salts and polymorphic forms of Afatinib
BR112014007310A2 (pt) 2011-09-27 2017-04-04 Novartis Ag 3-pirimidin-4-il-oxazolidin-2-onas como inibidores de idh mutante
EA031655B1 (ru) * 2014-02-11 2019-02-28 Байер Фарма Акциенгезельшафт Бензимидазол-2-амины в качестве ингибиторов midhi
US9951027B2 (en) * 2014-02-11 2018-04-24 Bayer Pharma Aktiengesellschaft Benzimidazol-2-amines as MIDH1 inhibitors
WO2016062677A1 (en) 2014-10-23 2016-04-28 Bayer Pharma Aktiengesellschaft Benzimidazol-2-amines as midh1 inhibitors
JP6672288B2 (ja) * 2014-10-23 2020-03-25 バイエル・ファルマ・アクティエンゲゼルシャフト 腫瘍の治療のためのmidh1阻害剤としての1−シクロヘキシル−2−フェニルアミノベンゾイミダゾール
EP3303302B1 (en) * 2015-06-08 2019-03-20 Bayer Pharma Aktiengesellschaft N-menthylbenzimidazoles as midh1 inhibitors
EP3319945B1 (en) 2015-07-07 2021-04-28 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts 2-aryl- and 2-arylalkyl-benzimidazoles as midh1 inhibitors
JP6824954B2 (ja) 2015-07-16 2021-02-03 ドイチェス クレープスフォルシュングスツェントルム シュティフトゥング デス エッフェントリッヒェン レヒツ mIDH1阻害剤としての5−ヒドロキシアルキルベンズイミダゾール
EP3121166A1 (en) 2015-07-21 2017-01-25 Bayer Pharma Aktiengesellschaft Fused imidazoles as midh1 inhibitors
TW201718513A (zh) 2015-07-27 2017-06-01 拜耳製藥公司 製備經取代之3-(2-苯胺-1-環己基-1h-苯并咪唑-5-基)丙酸衍生物之方法

Also Published As

Publication number Publication date
EP3328837A1 (en) 2018-06-06
AU2016300980A1 (en) 2017-12-21
NI201800014A (es) 2018-09-06
AU2016300980B2 (en) 2020-12-24
EA201890386A1 (ru) 2018-08-31
US20180222870A1 (en) 2018-08-09
CR20180053A (es) 2018-03-20
JP6804516B2 (ja) 2020-12-23
CA2993473A1 (en) 2017-02-02
ECSP18006465A (es) 2018-04-30
CN107810181B (zh) 2021-06-22
US10344004B2 (en) 2019-07-09
IL256024A (en) 2018-01-31
BR112018001534A2 (pt) 2018-09-11
PE20181038A1 (es) 2018-07-03
WO2017016992A1 (en) 2017-02-02
HK1252449A1 (zh) 2019-05-24
AR105493A1 (es) 2017-10-11
SV2018005621A (es) 2018-12-05
ES2860693T3 (es) 2021-10-05
JP2018521095A (ja) 2018-08-02
CN107810181A (zh) 2018-03-16
CL2018000249A1 (es) 2018-07-06
DOP2018000027A (es) 2018-02-28
EP3328837B1 (en) 2021-01-06
CO2018000793A2 (es) 2018-05-10
TN2018000038A1 (en) 2019-07-08
TW201708193A (zh) 2017-03-01
KR20180030789A (ko) 2018-03-26
MX2018001205A (es) 2018-04-24

Similar Documents

Publication Publication Date Title
CU20180014A7 (es) Inhibidor de la isocitrato deshidrogenasa mutada idh1 r132h
CL2017002854A1 (es) Sal de (s)-csa de s-ketamina, sal de (r)-csa de s-ketamina y procesos para la preparación de s-ketamin
CO2018003828A2 (es) Ácido (s) -3-amino-4- (difluorometilenil) ciclopent-1-eno-1-carboxílico, y compuestos relacionados como inactivadores de gaba aminotransferasa
EP3176173A4 (en) Crystalline free bases of c-met inhibitor or crystalline acid salts thereof, and preparation methods and uses thereof
EA201591889A1 (ru) 6-(5-гидрокси-1h-пиразол-1-ил)никотинамидные ингибиторы phd
EA201690473A1 (ru) Комбинированный состав двух противовирусных соединений
EA201692437A1 (ru) Комбинация
UY34305A (es) Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar
EA201591085A1 (ru) Композиция с отсроченным высвобождением, содержащая бигуанид
MX2017003627A (es) Composiciones de pirimidin quinolinona como inhibidores de isocitrato deshidrogenasa mutante (mt-idh).
EA201891347A1 (ru) Аза-бензимидазольные ингибиторы pad4
CO2018000795A2 (es) Método para preparar derivados de ácido 3-(2-anilino-1-ciclohexil-1h-bencimidazol-5-il)propanoico sustituido
AR088971A1 (es) INHIBIDOR DE a₁-PROTEINASA PARA DEMORAR EL COMIENZO O PROGRESION DE EXACERBACIONES PULMONARES
MX384794B (es) Proceso para la preparacion de 5-fluoro-1h-pirazoles a partir de hexafluoropropeno.
MX381092B (es) Inhibidores de fucosidasa.
EA201790191A1 (ru) Новые сульфониламинобензамидные соединения
EA201691999A1 (ru) Новые сульфониламинобензамидные соединения
IN2014MU00675A (es)
BR112016017087A8 (pt) forma cristalina alfa do composto monobenzoato a e seu método de preparação e composição farmacêutica compreendendo-a
BR112016015712A8 (pt) método de tratamento de doenças hepáticas.
EA201600012A1 (ru) Способ профилактики и/или лечения сердечно-сосудистых заболеваний
ECSP16024805A (es) Nuevo compuesto para el tratamiento de hipoglicemia severa
ECSP16024798A (es) Nuevo compuesto para el tratamiento de hipoglicemia severa
EP3118207A4 (en) Inclusion compound of 3&#39;,5&#39;-cyclicdiadenylic acid, and method for producing same
HK40005421A (en) Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase